Pharmacy Benefit Manager Accountability · October 2026

The middlemen are on trial.

A consolidated view of every active federal and state action against the pharmacy benefit managers — Caremark, Express Scripts, OptumRx and the GoodRx pricing alliance. Each status, judge, allegation and filing is tagged with a plain-English explainer. Hover anything.

Last reviewed June 11, 2026 · Sources: FTC Legal Library, U.S. District Court (D.R.I.), JPML, NCPA & plaintiff firms.

Recent updates

Major federal proceedings running in parallel

PBM & pricing-platform defendants under tracking

40+

Independent-pharmacy plaintiffs consolidated in MDL 3148

$7B

Projected 10-yr patient savings cited in the ESI settlement

Real-time status grid

Where each defendant stands in each proceeding, right now. A cell is a verdict-at-a-glance — hover for the why.

Rows = defendants
Columns = proceedings

Active / Contested Negotiating / Stayed Settled Pending ruling Not named

Case dossiers

The full file on each proceeding — court, judge, defendants, the legal theory, the latest docket entries, and who’s saying what.

State & legislative front

The courts aren’t the only battlefield. States and Congress are rewriting the rules PBMs operate under.

Executive Summary

The FTC front is settling out — and the private price-fixing war takes center stage.

After two years of pressure, the pharmacy-benefit-manager model is being challenged on every front at once. In February 2026 the FTC won a landmark consent settlement with Express Scripts in the insulin rebating case (Docket 9437), finalized June 10, 2026. That deal cracked the wall, and Caremark and OptumRx followed with proposed consent agreements of their own. But the distinction matters: Express Scripts is the only one of the three actually bound by a final order. The FTC announced its Caremark settlement in July and published the proposed order on August 5; public comment closed September 4, and the Commissioners have not voted to make it final. OptumRx’s proposed order is likewise still pending. On June 30, the 8th Circuit dismissed the PBMs’ constitutional countersuit against the FTC by mutual agreement. So the FTC front is winding down, not closed — a proposed order is a draft with a comment period, not a judgment.

In parallel, every major PBM faces a private antitrust war: independent pharmacies allege that the GoodRx ISP let competitors fix the prices they pay pharmacies — a textbook Sherman Act §1 claim now consolidated before one judge in Rhode Island.

The throughline: regulators and pharmacies are attacking the same machinery — rebate-driven pricing and DIR-style fee clawbacks — from two directions.

i.One final order, not three. All three PBMs have settled in principle, but only Express Scripts is bound by a final Commission order. Caremark’s and OptumRx’s remain proposed. The terms still matter: de-linked, transparent pricing is becoming the template for every PBM contract.
ii.The constitutional fight is over. The PBMs’ countersuit against the FTC was dismissed by the 8th Circuit on June 30 — mutually dropped now that all three have settled or proposed settlements.
iii.The pharmacy MDL is the main event. With the FTC front winding down, MDL 3148 is the live battleground. Briefing on the motion to dismiss has been complete since May, and Judge McElroy’s ruling — still outstanding — will decide whether the price-fixing theory survives to discovery.
iv.Watch arbitration. PBM contracts may force some pharmacies out of court — the single biggest threat to the class action.
v.The states are moving in. Florida’s Sept. 22 suit names the rebate aggregators — Zinc, Ascent and Emisar — directly, and reaches GLP-1s. An FTC consent order doesn’t stop a state from seeking its own damages.
vi.For employers: settlements are forcing transparency and de-linked pricing into standard PBM contracts. The next renewal is the moment to demand it.